Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC raised its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 6.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 662,594 shares of the company’s stock after purchasing an additional 38,490 shares during the period. Geode Capital Management LLC owned 1.26% of Janux Therapeutics worth $30,107,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares during the period. Ally Bridge Group NY LLC bought a new position in Janux Therapeutics in the 3rd quarter valued at about $4,943,000. Algert Global LLC acquired a new position in Janux Therapeutics during the 3rd quarter valued at about $1,112,000. FMR LLC raised its position in shares of Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after buying an additional 47,075 shares in the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of Janux Therapeutics in the 2nd quarter worth approximately $1,676,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 1.7 %

NASDAQ:JANX opened at $55.17 on Friday. The stock has a fifty day simple moving average of $54.35 and a 200 day simple moving average of $47.35. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -47.15 and a beta of 3.29. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. The company’s revenue for the quarter was down 82.6% compared to the same quarter last year. Equities analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the transaction, the insider now owns 6,887 shares of the company’s stock, valued at $318,454.88. The trade was a 12.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. purchased 1,200,000 shares of Janux Therapeutics stock in a transaction dated Friday, October 18th. The stock was bought at an average cost of $44.75 per share, with a total value of $53,700,000.00. Following the completion of the transaction, the director now directly owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 67,801 shares of company stock valued at $3,769,985 in the last three months. 29.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on JANX. UBS Group began coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, December 3rd. Leerink Partners raised their target price on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Finally, Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.